Supernus Pharmaceuticals reported $132.99M in Operating Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbott ABT:US USD 8.76B 123M
Ani Pharmaceuticals ANIP:US USD 92.41M 3.6M
Aurora Cannabis Inc ACB:CN CAD 150.25M 46.49M
Bristol Myers Squibb BMY:US USD 9.46B 716M
Canopy Growth Corp WEED:CN CAD 241.92M 35.6M
Cara Therapeutics CARA:US USD 34.57M 90K
Corcept Therapeutics CORT:US USD 80.56M 10.76M
Eisai 4523:JP JPY 179B 2.46B
Eli Lilly And LLY:US USD 5.47B 200.3M
Endo International Ordinary Shares ENDP:US USD 1.18B 1.13B
Horizon Pharma HZNP:US USD 768.1M 3.34M
Marinus Pharmaceuticals MRNS:US USD 37.17M 4.73M
Pacira Pharmaceuticals PCRX:US USD 181.85M 35.67M
Perrigo Ordinary Shares PRGO:US USD 1.12B 57.6M
Pfizer PFE:US USD 19.12B 5.9B
Revance Therapeutics RVNC:US USD 194.33M 87.83M
Supernus Pharmaceuticals SUPN:US USD 132.99M 45.88M
Teva Pharmaceutical Industries TEVA:US USD 4.74B 1.56B
United Therapeutics UTHR:US USD 315.9M 114.2M
Xeris Pharmaceuticals Inc XERS:US USD 48.31M 191K